

Maria Esperanza Rodriguez-Ruiz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7068487/publications.pdf>

Version: 2024-02-01

83
papers

6,541
citations

136740

32
h-index

133063

59
g-index

84
all docs

84
docs citations

84
times ranked

11081
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. <i>Cancer Discovery</i> , 2022, 12, 1356-1377.	7.7	22
2	Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. , 2022, 10, e003532.		8
3	Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. <i>Cancer Discovery</i> , 2022, 12, 1248-1265.	7.7	36
4	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18
5	Considerations for treatment duration in responders to immune checkpoint inhibitors. , 2021, 9, e001901.		69
6	Paradigms on Immunotherapy Combinations with Chemotherapy. <i>Cancer Discovery</i> , 2021, 11, 1353-1367.	7.7	197
7	Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils. <i>European Journal of Immunology</i> , 2021, 51, 2274-2280.	1.6	32
8	Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	24
9	Consolidating Radiotherapy with Immunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5443-5445.	3.2	4
10	Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8. <i>Journal of Pathology</i> , 2021, 255, 190-201.	2.1	49
11	Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. , 2021, 9, e002953.		23
12	CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. <i>Nature Communications</i> , 2021, 12, 7296.	5.8	22
13	Monitoring abscopal responses to radiation in mice. <i>Methods in Enzymology</i> , 2020, 635, 111-125.	0.4	2
14	Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. <i>Nature Immunology</i> , 2020, 21, 120-134.	7.0	218
15	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1 refractory tumors. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	51
16	CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. <i>Immunity</i> , 2020, 52, 856-871.e8.	6.6	387
17	Cellular cytotoxicity is a form of immunogenic cell death. , 2020, 8, e000325.		61
18	Endoscopic and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors. <i>OncImmunology</i> , 2020, 9, 1760676.	2.1	4

#	ARTICLE	IF	CITATIONS
19	Apoptotic caspases cut down the immunogenicity of radiation. <i>Oncolimmunology</i> , 2019, 8, e1655364.	2.1	19
20	Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. <i>Oncolimmunology</i> , 2019, 8, e1655964.	2.1	97
21	OC-0602 Pattern of care of radiotherapy practice for EBRT patients in Spain. <i>Radiotherapy and Oncology</i> , 2019, 133, S316-S317.	0.3	0
22	VISTA Blockade Immunotherapy in a MULTI-Modal Approach to Triple Negative Breast Cancer (TNBC) in MICE and IMPACT on Microbiome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S88-S89.	0.4	2
23	TGF β 2 Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 621-631.	1.9	68
24	Immunotherapeutic effects of intratumoral nanoplexed poly I:C. , 2019, 7, 116.		91
25	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. <i>Nature</i> , 2019, 569, 428-432.	13.7	313
26	Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. <i>Nature Medicine</i> , 2019, 25, 470-476.	15.2	459
27	Immune mechanisms mediating abscopal effects in radioimmunotherapy. , 2019, 196, 195-203.		52
28	Cytokines in clinical cancer immunotherapy. <i>British Journal of Cancer</i> , 2019, 120, 6-15.	2.9	720
29	Time for radioimmunotherapy: an overview to bring improvements in clinical practice. <i>Clinical and Translational Oncology</i> , 2019, 21, 992-1004.	1.2	13
30	Whole exome sequencing of germline DNA of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung adenocarcinoma (LUAD) according to KRAS status.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1540-1540.	0.8	1
31	Abstract 536: NBTXR3 potentiate cancer-cell intrinsic interferon beta response to radiotherapy. , 2019, , .		6
32	Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. <i>Annals of Oncology</i> , 2018, 29, 1312-1319.	0.6	106
33	Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4 α 1BB). <i>Oncolimmunology</i> , 2018, 7, e1368605.	2.1	7
34	Previous immunotherapy treatments may improve tumor responses with subsequent chemotherapy regimens. <i>Annals of Oncology</i> , 2018, 29, viii435-viii436.	0.6	0
35	Characterization through whole exome sequencing of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced non-small lung cancer (NSCLC). <i>Annals of Oncology</i> , 2018, 29, viii651-viii652.	0.6	0
36	Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. <i>Annals of Oncology</i> , 2018, 29, viii732.	0.6	8

#	ARTICLE	IF	CITATIONS
37	A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis. , 2018, 6, 96.		40
38	Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virusâ€Derived Vectors Fosters Dendritic Cellâ€Mediated T-cell Cross-Priming. Cancer Research, 2018, 78, 6643-6654.	0.4	60
39	International Symposium: Trailblazing in Cancer Immunotherapy, October 29â€31, 2017, Pamplona, Spain. Cancer Immunology, Immunotherapy, 2018, 67, 1809-1813.	2.0	0
40	Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. Trends in Immunology, 2018, 39, 644-655.	2.9	312
41	Abstract CT017: Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. , 2018, , .		1
42	Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).. Journal of Clinical Oncology, 2018, 36, e15155-e15155.	0.8	33
43	Abstract LB-151: Prophylactic TNFÎ± blockade unplugs toxicity and efficacy in immunotherapy anti-PD-1 + anti-CTLA-4 combinations. , 2018, , .		0
44	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	3.4	80
45	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Annals of Oncology, 2017, 28, 1988-1995.	0.6	326
46	Intratumoral Delivery of Immunotherapyâ€Act Locally, Think Globally. Journal of Immunology, 2017, 198, 31-39.	0.4	171
47	Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. Brachytherapy, 2017, 16, 1246-1251.	0.2	32
48	Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treatment Reviews, 2017, 60, 24-31.	3.4	262
49	Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy. Clinical Cancer Research, 2017, 23, 5326-5328.	3.2	33
50	Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium. International Journal of Radiation Oncology Biology Physics, 2017, 97, 389-400.	0.4	55
51	Combined immunotherapy encompassing intratumoral polyICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Annals of Oncology, 2017, 28, xi14.	0.6	0
52	Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2017, 35, 3002-3002.	0.8	129
53	Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy. Cancer Discovery, 2016, 6, 1312-1314.	7.7	41
54	Emerging Opportunities and Challenges in Cancer Immunotherapy. Clinical Cancer Research, 2016, 22, 1845-1855.	3.2	242

#	ARTICLE	IF	CITATIONS
55	Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop. <i>Cancer Research</i> , 2016, 76, 2863-2867.	0.4	4
56	Deciphering CD137 (4-1BB) signaling in T cell costimulation for translation into successful cancer immunotherapy. <i>European Journal of Immunology</i> , 2016, 46, 513-522.	1.6	104
57	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. <i>Tumor Biology</i> , 2016, 37, 13687-13694.	0.8	37
58	Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. <i>Cancer Research</i> , 2016, 76, 5994-6005.	0.4	191
59	Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. <i>Oncolmmunology</i> , 2016, 5, e1062967.	2.1	52
60	Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 493-497.	2.0	15
61	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 524-536.	0.5	48
62	Study of kidney damage in pediatric patients with neurogenic bladder and its relationship with the pattern of bladder function and treatment received. <i>Actas Urológicas Españolas (English Edition)</i> , 2016, 40, 37-42.	0.2	2
63	Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. <i>Cancer Discovery</i> , 2016, 6, 71-79.	7.7	356
64	Abstract 4908: Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires Batf3-dependent dendritic cells. , 2016, , .		4
65	Abstract 4015: Exposure of lymphatic endothelial cells to ionizing radiation increases the surface expression levels of integrin ligands. , 2016, , .		0
66	Abstract 4012: Improving radiotherapy abscopal effects with anti-PD1 and anti-CD137-based immunotherapy. , 2016, , .		0
67	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2 ^{-/-} /IL2R ^β null Immunodeficient Mice. <i>Cancer Research</i> , 2015, 75, 3466-3478.	0.4	137
68	Pneumomediastinum as a complication of SABR for lung metastases. <i>Radiation Oncology</i> , 2015, 10, 25.	1.2	1
69	Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. <i>Seminars in Oncology</i> , 2015, 42, 640-655.	0.8	179
70	Functional expression of CD137 (4-1BB) on T helper follicular cells. <i>Oncolmmunology</i> , 2015, 4, e1054597.	2.1	15
71	Abstract 261: Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2 ^{-/-} /IL2R ^β null immunodeficient mice. , 2015, , .		3
72	Abstract 4058: Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
73	Phase I Study with Immunotherapy with Dendritic Cells (Dc) Combined with Intratumoral Hiltonol in Patients with Advanced Cancer. <i>Annals of Oncology</i> , 2014, 25, iv371.	0.6	0
74	Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins. <i>Clinical Cancer Research</i> , 2014, 20, 5697-5707.	3.2	200
75	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. <i>Current Opinion in Immunology</i> , 2014, 27, 89-97.	2.4	111
76	Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed. <i>Journal of Translational Medicine</i> , 2014, 12, 98.	1.8	13
77	Phase II trial of image-based high-dose-rate interstitial brachytherapy for previously irradiated gynecologic cancer. <i>Brachytherapy</i> , 2014, 13, 219-224.	0.2	26
78	A proposal for the stratification of the risk of locoregional failure after surgical resection, perioperative high dose rate brachytherapy, and external beam irradiation: The University of Navarre predictive model. <i>Brachytherapy</i> , 2014, 13, 400-404.	0.2	6
79	Randomized phase II study with dendritic cell (DC) immunotherapy in patients with resected hepatic metastasis of colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3129-TPS3129.	0.8	0
80	Phase II study with immunotherapy with dendritic cells (DC) and intratumoral hiltonol in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3113-TPS3113.	0.8	0
81	Patterns of Failure in Patients With Glioblastoma Treated With Surgery and Intensity Modulated Radiation Therapy and Temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S273.	0.4	0
82	Induction Chemotherapy (I-CHT) Followed by Intensity Modulated Radiation Therapy Using Simultaneously Integrated Boost (IMRT-SIB) and Concomitant Chemotherapy and Cetuximab (C-CHT) for Locally Advanced Squamous Head-and-Neck Carcinomas (SHNC).. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S527.	0.4	0
83	Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review.. <i>Radiation Oncology</i> , 2012, 7, 50.	1.2	21